Precision Medicine in Oncology

The AJMC® Precision Medicine in Oncology compendium is a comprehensive resource for clinical news and expert insights for molecular profiling of tumors.

Latest News

May 2024 News From Strategic Alliance Partners
May 2024 News From Strategic Alliance Partners

May 20th 2024

Florida Cancer Specialists & Research Institute launches a new precision medicine venture; Tennessee Oncology announces promotions.

New KRYSTAL-1 Data Show 90% Intracranial Disease Control Rate in Patients With KRAS G12C–Mutated NSCLC and Untreated CNS Metastases
New KRYSTAL-1 Data Show 90% Intracranial Disease Control Rate in Patients With KRAS G12C–Mutated NSCLC and Untreated CNS Metastases

August 16th 2023

ASCO 2023 logo
ASCO 2023: Solid Tumors

July 31st 2023

Cathy Eng, MD
FDA Sets Priority Review for Fruquintinib as ASCO Data Confirm Safety Results

June 20th 2023

ACC 2023 Coverage: Topics in Cardio-oncology
ACC 2023 Coverage: Topics in Cardio-oncology

April 18th 2023

More News

Partnership to Find Patients With NRG1 Fusions for Zenocutuzumab Trial in Pancreatic Cancer
August 17th 2020

Partnership to Find Patients With NRG1 Fusions for Zenocutuzumab Trial in Pancreatic Cancer

Mary Caffrey
An agreement will tap Caris Life Sciences' next-generation sequencing technology to identify patients for Merus’ phase 1/2 eNRGy trial.
Rethinking Downside Risk Protection Amid Growth in Precision Medicine
August 16th 2020

Rethinking Downside Risk Protection Amid Growth in Precision Medicine

Keely Macmillan, MSPH
Oncology drug costs affect those entering into risk-based arrangements, and these groups must rethink their approach to evaluating risk.
How DNA Medicines Could Transform Treatment of Glioblastoma Multiforme
August 14th 2020

How DNA Medicines Could Transform Treatment of Glioblastoma Multiforme

Jeffrey Skolnick, MD
Better technology is rekindling the promise of DNA medicines in oncology, including the treatment of glioblastoma.
DNA picture
August 12th 2020

NGS, Liquid Biopsy Combined to Detect Specific Mutation in NSCLC

AJMC Staff
It is the first such approval for a diagnostic that combines next-generation sequencing and liquid biopsy in one test.
FDA Clears clonoSEQ to Detect MRD in Chronic Lymphocytic Leukemia
August 6th 2020

FDA Clears clonoSEQ to Detect MRD in Chronic Lymphocytic Leukemia

AJMC Staff
clonoSEQ, from Adaptive Biotechnologies, can detect 1 cancer cell among a million healthy cells.
ctDNA Shows Utility as Predictive Biomarker for Pembrolizumab Therapy
August 6th 2020

ctDNA Shows Utility as Predictive Biomarker for Pembrolizumab Therapy

Maggie L. Shaw
Results from a phase 2 trial of pembrolizumab as immune checkpoint inhibition against 5 types of solid tumors show that circulating tumor DNA (ctDNA) may be used to accurately predict response to treatment.
Vaccine Plus Pembrolizumab Shows Promise in Breast Cancer in Animal Study
August 1st 2020

Vaccine Plus Pembrolizumab Shows Promise in Breast Cancer in Animal Study

AJMC Staff
The study, using mice, also found that the 2-step therapy was more effective the earlier it was given.
lung cancer
July 31st 2020

Osimertinib Granted Breakthrough Status for Early-Stage, EGFR-Mutated NSCLC Patients After Surgery

Mary Caffrey
The ADAURA trial was stopped in April 2020 after an independent monitoring committee called for the trial to be unblinded 2 years early based on a determination of overwhelming efficacy.
Algorithm Identifies Noncoding Genetic Mutations That Play Role in 5 Pediatric Cancers
July 24th 2020

Algorithm Identifies Noncoding Genetic Mutations That Play Role in 5 Pediatric Cancers

Allison Inserro
Using a computational algorithm, researchers at Children's Hospital of Philadelphia analyzed noncoding genetic mutations to discover how they factor into 5 pediatric cancers.
Site Logo
July 22nd 2020

ASCO 2020: Genetic Testing

Mary Caffrey Allison Inserro Peter Wehrwein
Four studies were highlighted that amplified the 3 components of using genetic testing in cancer treatment and prevention: (1) understanding the germline component of a tumor test, (2) broadening access to genetic counselors with video sessions, and (3) making sure risk assessment of each patient is accurate, so that patients do not have unnecessary surgeries.
Site Logo
July 20th 2020

ASCO 2020: Clinical Updates

Mary Caffrey Maggie L. Shaw
Featuring findings from the KEYNOTE-177, ARAURA, ASPEN, and CITYSCAPE trials, and new results from MURANO.
Cancer Organizations Ask Trump Administration to Maintain Relationship With WHO
July 19th 2020

Cancer Organizations Ask Trump Administration to Maintain Relationship With WHO

AJMC Staff
US cancer researchers benefit from the exchange of information with the World Health Organization (WHO), which helps domestic patients as well as international ones.
Roche Invests in Blueprint Medicines, Maker of RET Inhibitor Pralsetinib
July 15th 2020

Roche Invests in Blueprint Medicines, Maker of RET Inhibitor Pralsetinib

Allison Inserro
Pralsetinib, an investigational precision therapy in late-stage development for individuals with alterations in the RET gene, would be jointly sold in the United States by the 2 companies if it is approved.
Large Survival Edge in Lung Cancer With Companion Diagnostics, but Some Still Miss Out, Study Finds
July 10th 2020

Large Survival Edge in Lung Cancer With Companion Diagnostics, but Some Still Miss Out, Study Finds

Mary Caffrey
Companion diagnostic testing identifies patients most likely to benefit from biomarker-driven treatments. Much of the promise in lung cancer treatment comes from use of testing to match patients with targeted therapies, checkpoint inhibitors, or combinations.
Payer Coverage for Liquid Biopsies Improves, but Gaps Remain, Study in JNCCN Finds
July 8th 2020

Payer Coverage for Liquid Biopsies Improves, but Gaps Remain, Study in JNCCN Finds

Mary Caffrey
JNCCN is the official journal of the National Comprehensive Cancer Network, a group of cancer centers that develops treatment guidelines that are considered the “gold standard” for payers.
Can Artificial Intelligence Detect Early-Stage Pancreatic Cancer?
July 2nd 2020

Can Artificial Intelligence Detect Early-Stage Pancreatic Cancer?

Allison Inserro
Using artificial intelligence to comb through electronic health records to look for the subtle signs that individuals often present with to their doctor in the years before a more advanced diagnosis of pancreatic cancer is made showed promise in a early trial to see if earlier detection is possible.
Pembrolizumab Approved for First-Line Treatment of Patients With Colorectal Cancer and Key Mutations
June 30th 2020

Pembrolizumab Approved for First-Line Treatment of Patients With Colorectal Cancer and Key Mutations

Mary Caffrey
The decision comes almost exactly a month after results from KEYNOTE-177 were presented at the annual meeting of the American Society of Clinical Oncology.
Young Adults With Cancer More Likely to Have Germline Mutations, Study Finds
June 27th 2020

Young Adults With Cancer More Likely to Have Germline Mutations, Study Finds

Jared Kaltwasser
Patients between the ages of 18 and 39 who are diagnosed with solid-tumor cancers are more likely than the general population to have germline mutations that could make them more susceptible to secondary primary cancers, according to new research.
What Do Real-World Data Show for Adjuvant Immunotherapy in Melanoma?
June 26th 2020

What Do Real-World Data Show for Adjuvant Immunotherapy in Melanoma?

AJMC Staff
Having lower socioeconomic status, comorbidities, or being covered by Medicare was associated with less receipt of immunotherapy for stage III melanoma.
Site Logo
June 19th 2020

Will the Pandemic Change How Health Care Uses Advanced Technologies?

Allison Inserro
Panelists at the AHIP Institute & Expo Online discussed whether algorithms will play a greater role in the future in reallocating health care resources.
Site Logo
June 17th 2020

Addressing the Gap in Precision Medicine

David A. Fabrizio, BS
We need the development of new, complex biomarkers to address the increasing complexity in treatment modalities that, in and of themselves, have characteristics of a continuous variable; they require innovation and outcomes data, which perhaps will be partly addressed by some of the emerging real-world evidence databases amassed by pairing sequence information and clinical outcomes. Tumor mutational burden is a great example of this innovation in practice.
FDA Approves Second Biomarker-Based Indication for Pembrolizumab
June 17th 2020

FDA Approves Second Biomarker-Based Indication for Pembrolizumab

Gianna Melillo
The FDA today granted accelerated approval to the second biomarker-based indication for Merck’s pembrolizumab (Keytruda), an anti-PD-1 therapy, regardless of tumor type. A companion diagnostic to pembrolizumab, FoundationOne CDx was also today approved by the FDA as only approved companion diagnostic to measure tumor mutational burden.
Zanubrutinib Shows Promise in Marginal Zone Lymphoma at EHA
June 13th 2020

Zanubrutinib Shows Promise in Marginal Zone Lymphoma at EHA

AJMC Staff
Research at the European Hematology Association featured zanubrutinib as monotherapy and in combination with rituximab, and well as evaluations of biomarkers that signal responses.
Struggles in Developing Precision Medicine for Gastroesophageal Cancers
June 13th 2020

Struggles in Developing Precision Medicine for Gastroesophageal Cancers

Allison Inserro
The challenges in precision oncology in gastric cancer is driven by its inter- and intra-tumoral heterogeneity, leaving chemotherapy as the standard of care.
Study Probes Genomic Factors Affecting Outcomes in Advanced Renal Cancer
June 6th 2020

Study Probes Genomic Factors Affecting Outcomes in Advanced Renal Cancer

AJMC Staff
Features typically linked to immunotherapy response or resistance in other types of cancer don’t work the same way in advanced clear cell renal cell carcinoma when treated with programmed death 1 inhibitors.
Study Shows How NGS, Precision Medicine Benefitted Patients at Community Cancer Clinic
May 30th 2020

Study Shows How NGS, Precision Medicine Benefitted Patients at Community Cancer Clinic

Allison Inserro
Physicians at a community oncology clinic center have an increased understanding of the clinical utility of molecular testing after implementing next generation sequencing and precision medicine, said researchers.
FDA Approves Olaparib for HRR Gene–Mutated Metastatic Castration-Resistant Prostate Cancer
May 20th 2020

FDA Approves Olaparib for HRR Gene–Mutated Metastatic Castration-Resistant Prostate Cancer

Allison Inserro
The therapy is for patients with deleterious or suspected deleterious germline somatic homologous recombination repair (HRR) gene–mutated cancer or for those whose cancer has progressed after prior treatment with enzalutamide or abiraterone.
FDA OKs Atezolizumab for Initial Treatment for Certain NSCLC Patients With High PD-L1 Expression
May 19th 2020

FDA OKs Atezolizumab for Initial Treatment for Certain NSCLC Patients With High PD-L1 Expression

AJMC Staff
The approval is the fifth for the immunotherapy in lung cancer and the fourth in non–small cell lung cancer (NSCLC).
FDA Approves Qinlock (Ripretinib) For Gastrointestinal Stromal Tumors
May 18th 2020

FDA Approves Qinlock (Ripretinib) For Gastrointestinal Stromal Tumors

Gianna Melillo
The FDA approved Deciphera Pharmaceuticals’ ripretinib (Qinlock), the first drug for fourth-line treatment of advanced gastrointestinal stromal tumors (GISTs). The medication is only indicated for adults who have previously received treatment with 3 or more kinase inhibitor therapies, including imatinib.
Study Describes Use of Liquid Biopsy in Patients With Solid Tumors
May 16th 2020

Study Describes Use of Liquid Biopsy in Patients With Solid Tumors

AJMC Staff
A recent study describes the use of a liquid assay to uncover any links between response to treatment and tumor load score in patients with stage 2 or stage 3 cancer with solid tumors. Circulating tumor DNA is linked with more advanced cancer.
<12345678910
...
13>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo